MDM2 Antagonists Counteract Drug-Induced DNA Damage-Reference-Cited by-同舟云学术

MDM2 Antagonists Counteract Drug-Induced DNA Damage

Published:2017-10 Issue: Volume:24 Page:43-55
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Vilgelm Anna E.,Cobb Priscilla,Malikayil Kiran,Flaherty David,Andrew Johnson C.,Raman Dayanidhi,Saleh Nabil,Higgins Brian,Vara Brandon A.,Johnston Jeffrey N.,Johnson Douglas B.,Kelley Mark C.,Chen Sheau-Chiann,Ayers Gregory D.,Richmond Ann

Funder

Department of Veterans Affairs

NIH

Harry J. Lloyd Charitable Trust

Vanderbilt Clinical Oncology Career Development program

Vanderbilt Ingram Cancer Center

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference55 articles.

1. p21 in cancer: intricate networks and multiple activities;Abbas;Nat. Rev. Cancer,2009

2. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence;Aird;Cell Rep.,2013

3. Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia;Andreeff;Clin. Cancer Res.,2016

4. RNA-targeted therapeutics in cancer clinical trials: current status and future directions;Barata;Cancer Treat. Rev.,2016

5. Nucleotide deficiency promotes genomic instability in early stages of cancer development;Bester;Cell,2011

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia;Biomedicines;2024-06-22

2. RNA-Sequencing Reveals Candidate Genes/Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia;2024-01-25

3. Hydroquinone reduces DNA replication tolerance to stress and increases chemotherapy sensitivity in oral squamous cell carcinoma;Materials Express;2023-05-01

4. Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells;Oncotarget;2023-03-11

5. BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis;Cell Reports;2022-12